1. Home
  2. XPRO vs ANIP Comparison

XPRO vs ANIP Comparison

Compare XPRO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expro Group Holdings N.V.

XPRO

Expro Group Holdings N.V.

HOLD

Current Price

$18.31

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$75.17

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPRO
ANIP
Founded
1938
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2013
1999

Fundamental Metrics

Financial Performance
Metric
XPRO
ANIP
Price
$18.31
$75.17
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$14.00
$107.33
AVG Volume (30 Days)
1.0M
357.8K
Earning Date
05-19-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.45
2.15
Revenue
$522,493,000.00
$206,547,000.00
Revenue This Year
N/A
$44.10
Revenue Next Year
$1.72
$13.18
P/E Ratio
$39.53
$36.17
Revenue Growth
14.89
2.47
52 Week Low
$6.70
$54.10
52 Week High
$18.38
$99.50

Technical Indicators

Market Signals
Indicator
XPRO
ANIP
Relative Strength Index (RSI) 69.52 35.82
Support Level $12.18 $62.89
Resistance Level N/A $77.00
Average True Range (ATR) 0.96 2.65
MACD 0.12 -0.34
Stochastic Oscillator 85.39 2.16

Price Performance

Historical Comparison
XPRO
ANIP

About XPRO Expro Group Holdings N.V.

Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: